Navigation Links
Katherine A. High, M.D., to present 2013 American Society of Hematology E. Donnall Thomas Lecture
Date:8/1/2013

(WASHINGTON, August 1, 2013) The American Society of Hematology (ASH) will honor Katherine A. High, MD, of the Howard Hughes Medical Institute and The Children's Hospital of Philadelphia with the 2013 E. Donnall Thomas Lecture and Prize for her unparalleled work to identify the molecular basis of hemophilia and to develop novel genetic therapies to treat the disorder. Named for the late Nobel Prize laureate and past Society president E. Donnall Thomas, MD, this lectureship and prize recognizes pioneering research achievements in hematology that have helped move the field forward.

Dr. High will present her lecture, "Sailing to Ithaca: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product," at 9:00 a.m. on Monday, December 9, at the 55th ASH Annual Meeting and Exposition in New Orleans. Her lecture will explore the use of gene therapies for the treatment of inherited disorders, discussing the therapeutic successes of laboratory and small-scale clinical studies conducted over the last two decades as well as the obstacles that remain to bring this seemingly straightforward yet extremely nuanced concept to successful clinical application. During her lecture Dr. High will also discuss the sustained clinical improvements yielded in the setting of inherited retinal degenerative diseases and of hemophilia B by the use of in vivo gene transfer with adeno-associated virus (AAV) vectors. She will reflect on how a rigorous understanding of the interaction of AAV vectors with the human immune response, and other homeostatic mechanisms, has allowed investigators to harness the power of gene identification and gene delivery vectors to provide long-lasting therapeutic outcomes for previously incurable diseases.

As a leading expert in gene therapy of hemophilia, Dr. High has dedicated her career to bringing this novel and complex concept to fruition. Her work has ranged from basic biochemical investigations of clotting factors, virology of the AAV viruses as relevant to vector design, dissection of the human immune response to vector and transgene proteins, development of predictive large animal models, and iterative careful and highly instructive clinical trials. Her more than 15 years of investigation regarding the feasibility of gene therapy for hemophilia has culminated in successful clinical studies utilizing AAV vector-mediated gene transfer for the treatment of hemophilia B.

Dr. High is a Howard Hughes Medical Institute Investigator, the William H. Bennett Professor of Pediatrics at the University of Pennsylvania School of Medicine, and an attending physician at the Children's Hospital of Philadelphia. She received her medical degree from the University of North Carolina School of Medicine and completed her Hematology fellowship at Yale University School of Medicine. Dr. High was named as a Howard Hughes Medical Institute Investigator in 2003 and is also an elected member of both the Institute of Medicine and the American Academy of Arts & Sciences. She is a member and former Councillor of ASH, a former president of the American Society of Gene and Cell Therapy, and a member of the International Society of Thrombosis and Hemostasis.

"Dr. High is unquestionably a leader in gene therapy and has made remarkable, ground-breaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles," said ASH President Janis L. Abkowitz, MD, of the University of Washington. "Through her countless discoveries, Dr. High has transformed the notion of utilizing genetically engineered mechanisms for treatment of incurable inherited disorders from a distant vision to reality."


'/>"/>

Contact: Kaitlin Bressler
202-552-4925
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares
2. U.S. Health Care Spending High, But Quality Lags: Report
3. Evolution May Explain Runners High, Study Says
4. Global Tobacco Use Remains High, Survey Finds
5. Childhood Vaccination Rates Remain High, CDC Says
6. Edith Mitchell, M.D., FACP, named 2012 recipient of ASCO Humanitarian Award
7. ASH awards Timothy J. Ley, M.D., with 2012 E. Donnall Thomas Lecture and Prize
8. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
9. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
10. Penn Medicines Daniel J. Rader, M.D., receives AHAs Clinical Research Prize
11. Richard Mayeux, M.D., M.S., elected Fellow of AAAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: